Alcohol Clinical Trials in Los Angeles, California
17 recruitingLos Angeles, California
Showing 1–17 of 17 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled296 locationsNCT06419374
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled342 locationsNCT06318169
Recruiting
Phase 2
Human Laboratory Study of Apremilast for Alcohol Use Disorder
Alcohol Use DisorderAlcohol Misuse
National Institute on Alcohol Abuse and Alcoholism (NIAAA)100 enrolled3 locationsNCT07325266
Recruiting
Phase 2
Motivation for IV Alcohol Self-Administration in Humans
Alcohol Use Disorder
University of California, Los Angeles210 enrolled1 locationNCT06494891
Recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled318 locationsNCT06528314
Recruiting
Phase 3
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Alcohol Use Disorder
Eli Lilly and Company1,100 enrolled119 locationsNCT07219966
Recruiting
Phase 3
A Study of Brenipatide in Participants With Alcohol Use Disorder
Alcohol Use Disorder
Eli Lilly and Company1,100 enrolled114 locationsNCT07219953
Recruiting
Phase 3
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline1,200 enrolled49 locationsNCT07221227
Recruiting
Phase 3
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline1,250 enrolled43 locationsNCT07221188
Recruiting
Phase 2
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Liver Diseases, Alcoholic
GlaxoSmithKline393 enrolled131 locationsNCT06613698
Recruiting
Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
Alcoholic Cirrhosis
Indiana University196 enrolled2 locationsNCT04250259
Recruiting
Phase 2
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
CirrhosisCirrhosis, LiverCirrhosis Due to Hepatitis B+5 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)256 enrolled13 locationsNCT05832229
Recruiting
Phase 2
Tirzepatide for Alcohol Use Disorder
Obesity and OverweightAlcohol Use DisorderAlcohol
University of Southern California42 enrolled1 locationNCT06994338
Recruiting
Not Applicable
Social Facilitation of Alcohol Effects and Alcohol Misuse in Young Adults
Alcohol ConsumptionAlcohol Abuse/Dependence
University of Southern California200 enrolled1 locationNCT06627803
Recruiting
Phase 2
Suvorexant for Treatment of AUD and PTSD
InsomniaPost Traumatic Stress Disorder (PTSD)Alcohol Use Disorder (AUD)
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance76 enrolled2 locationsNCT06679062
Recruiting
Not Applicable
Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure
Attention Deficit Hyperactivity DisorderFetal Alcohol Spectrum Disorders
University of California, Los Angeles30 enrolled1 locationNCT06847165
Recruiting
Not Applicable
CM for Patients With ALD After Liver Transplant
Alcohol Use DisorderContingency ManagementAlcohol Liver Disease+2 more
Arpan A. Patel, MD30 enrolled1 locationNCT06304467